Chester County News and Community Website
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has dosed the first patient in a Phase 1 trial of CT-202, moving its Nectin-4 x CD3 bispecific antibody into human testing …
Context Therapeutics Starts Phase 1 Trial of CT-202 Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) is discontinuing development of one cancer drug candidate and concentrating capital on two clinical programs as its second-quarter net loss widened to …
Context Therapeutics Narrows Pipeline as Quarterly Loss Widens Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) recently granted a new employee an option to purchase 146,000 shares at 70 cents each, using equity compensation outside its existing incentive …
Context Grants 146,000-Share Option to New Employee Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) granted stock options covering 146,000 shares to a newly hired employee under a Nasdaq inducement award provision, a compensation mechanism commonly used …
Context Therapeutics Grants New-Hire Equity Award Under Nasdaq Rule Read More PHILADELPHIA, PA — Context Therapeutics (Nasdaq: CNTX) amended its licensing agreement with BioAtla (Nasdaq: BCAB) to eliminate future milestone and royalty payments tied to its CT-202 cancer program, a move …
Context Therapeutics Buys Out CT-202 Royalty Obligations Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) expects interim clinical data from two experimental cancer therapies later this year as the biotechnology company advances multiple bispecific antibody programs targeting …
Context Therapeutics Advances Cancer Drug Pipeline Toward Data Readouts Read More PHILADELPHIA, PA — Context Therapeutics Inc. (NASDAQ: CNTX) said it has granted non-qualified stock option awards covering a total of 120,000 shares of common stock to two newly hired employees …
Context Therapeutics (NASDAQ: CNTX) Issues Equity Awards to Attract New Talent Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) reported third-quarter 2025 financial results and provided an update on its pipeline of bispecific T cell engager (TCE) programs, highlighting early signs …
Context Therapeutics Reports Encouraging Early Data in Cancer Trials, Eyes 2026 Milestones Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced it will present at two upcoming investor conferences in November, highlighting its growing pipeline of T cell–engaging bispecific antibodies for solid …
Context Therapeutics to Showcase Cancer Immunotherapy Advances at Investor Events Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced that it will present new clinical and preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking …
Context Therapeutics to Present New Data on Two Bispecific T Cell Engagers at SITC 2025 Read More